Sign in

Trial result ·

A Multicenter, open-label, randomized, non-inferiority trial of 8 versus 12 weeks of sofosbuvir/ravidasvir treatment in non-cirrhotic patients with chronic hepatitis C virus infection (EASE trial).

Written based on 1 research study on PubMed, searched on 13 Nov 2026.

What was studied

This trial tested a hepatitis C drug pair called sofosbuvir/ravidasvir. It asked if 8 weeks of the drugs work as well as 12 weeks. The people were adults aged 18 to 69 with long-term hepatitis C. None of them had cirrhosis. The trial ran at hospitals and 17 local health centers in Malaysia. People were split by chance into an 8-week or a 12-week group. Both people and doctors knew which group each person was in.

What they found

From March 2021 to March 2023, 322 people joined, 161 per group. The main test was whether the virus was gone 12 weeks after the drugs ended. In the 8-week group, this was true for 142 of 152 people. In the 12-week group, it was true for 143 of 153 people. The authors say the shorter course was not worse than the longer one. Results were alike across virus types, virus levels, and people with HIV. Side effects were similar in both groups and mostly mild. No serious side effects were linked to the drugs.

What it means for patients

The authors conclude that 8 weeks of these drugs worked about as well as 12. They also say the shorter course was well tolerated. This applies to adults with hepatitis C who do not have cirrhosis. The authors say more studies are needed before wide use.

Why it is not certain yet

People with missing main results were left out of the main analysis. Everyone knew which course they got, which can affect results. The trial did not include people with cirrhosis. It also only included adults aged 18 to 69 in Malaysia. The authors say studies on real-world use and costs are still needed.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

A Multicenter, open-label, randomized, non-inferiority trial of 8 versus 12 weeks of sofosbuvir/ravidasvir treatment in non-cirrhotic patients with chronic hepatitis C virus infection (EASE trial).

PubMed · PMID 42140479

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Liver cirrhosis publications